An observational study in Graft Versus Host Disease, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by The First Affiliated Hospital of Soochow University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.
Among the 81 studies in Graft vs Host Disease with a site in China, this one is one of 7 that started in 2020, is one of 9 observational ones, reaches primary completion later than 16 of the 42 other live ones, and was the 28th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.
Browse Graft vs Host Disease studies →38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 8–18
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Sites in China
Ages 3–17
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 14 · Phase 4 8
First in 2003; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 72 across 98 observational studies indexed under Graft vs Host Disease.
Median enrollment 53 across the 72 interventional studies, 50 across the 9 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 81 have an industry lead sponsor. The 10 most frequent:
The First Affiliated Hospital of Soochow University is the lead sponsor of 264 studies on the registry; 150 are open to participants now.
The First Affiliated Hospital of Soochow University has 7 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Graft vs Host Disease with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07047456Phase 3Anhui Provincial HospitalEffect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT | 2026-12-31 |
| NCT06677255Wuhan Optics Valley Vcanbiopharma Co., Ltd.A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment | 2026-12 |
| NCT04660487The First Affiliated Hospital of Soochow UniversityRelationship Between "FODMAPs" and "GVHD" | 2026-12-01 |
| NCT07350057Shanghai Jiao Tong University School of MedicineA Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graft-versus-Host Disease After Haploidentical Stem Cell Transplantation in Children | 2027-01-31 |
| NCT07725263Haikou Affiliated Hospital of Central South University Xiangya School of MedicineLow-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 81 studies in Graft vs Host Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
With the stem cell transplanting increasing, patients which effected with "GVHD" were also increased. To evaluation the relationship between "FODMAPs" and "GVHD", Bone marrow transplant patients were recruited.
The feces were collected from the patients who had been successfully transplanted after bone marrow transplantation. After 24 hours of culture in the culture medium, the degradation rate of "FODMAPs" was detected, and the relationship between the degradation rate and the occurrence time and degree of "GVHD" was observed
Successful bone marrow colonization after bone marrow transplantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Occurrence of GVHD
The occurrence time and degree of GVHD
Time frame: 90 days
Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.
Of 45 non-industry observational studies under Graft vs Host Disease, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 154. This study's planned 72 months is above that.
Counting every sponsor, half of 46 studies reached it within 60 months; a quarter within 37 and three quarters within 154.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Soochow University →